BridgeBio Pharma
BBIO
197 hedge funds and large institutions have $2.58B invested in BridgeBio Pharma in 2023 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 70 increasing their positions, 58 reducing their positions, and 44 closing their positions.
28% more call options, than puts
Call options by funds: $120M | Put options by funds: $93.5M
21% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 58
2% more capital invested
Capital invested by funds: $2.53B → $2.58B (+$43.2M)
1.81% less ownership
Funds ownership: 95.15% → 93.34% (-1.8%)
8% less funds holding
Funds holding: 213 → 197 (-16)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
34% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 44
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$29M |
| 2 |
LCM
Laurion Capital Management
New York
|
+$18.6M |
| 3 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$16.4M |
| 4 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$12.3M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$9.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIG
American International Group
New York
|
-$26M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$18M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$16.6M |
| 4 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$14.8M |
| 5 |
Renaissance Technologies
New York
|
-$12.7M |
BBIO Hedge Fund Activity: Q2 2023 in Review
197 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q2 2023, worth a combined $2.58B — up 1.7% from $2.53B a quarter earlier.
Sellers outnumbered buyers: 44 funds closed out of BBIO and 29 opened new positions — a net loss of 15 holders — while 58 trimmed existing stakes and 70 added.
The largest buyer was State Street, adding an estimated $29M. The largest seller was American International Group, cutting an estimated $26M.
- 197 institutional investors held BridgeBio Pharma (BBIO) as of Q2 2023, down from 213 in Q1 2023.
- Funds reported $2.58B of BridgeBio Pharma stock for Q2 2023, up 1.7% quarter-over-quarter.
- 29 funds opened new BridgeBio Pharma positions in Q2 2023 and 44 closed out, a net change of -15 holders.
- The largest BridgeBio Pharma buyer in Q2 2023 was State Street, an estimated $29M added.
- The largest BridgeBio Pharma seller in Q2 2023 was American International Group, an estimated $26M sold.
Based on aggregated 13F filings for Q2 2023.